Login
$LAB
$0.60 -$0.11 (15.04%) Live

$LAB SEC Filings

Filed On Filing
16 Nov 2026 425
16 Nov 2026 8-K: Other Events

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

05 Nov 2026 Form 4: Carey Thomas D., Director

Bought 75,000 shares ($46.9K)

03 Nov 2026 10-Q
03 Nov 2026 425
03 Nov 2026 8-K: Regulation FD Disclosure

ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific

30 Oct 2026 424B3
21 Oct 2026 EFFECT
21 Oct 2026 424B3
21 Oct 2026 S-4/A
09 Oct 2026 S-4/A
05 Oct 2026 425
05 Oct 2026 8-K: Regulation FD Disclosure

Boston, Mass., October, 5, 2026 – Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED (“ARCHIMED”), a leadi...

30 Sep 2026 425
30 Sep 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

09 Sep 2026 S-4/A
24 Aug 2026 Form 4: Mackay Sean, SVP & Chief Business Officer

Gave up 25,729 shares to cover exercise price or tax ($17.3K)

24 Aug 2026 Form 4: Kim Hanjoon Alex, Chief Financial Officer

Gave up 28,195 shares to cover exercise price or tax ($18.9K)

24 Aug 2026 Form 4: Egholm Michael, Director

Gave up 97,627 shares to cover exercise price or tax ($65.6K)

14 Aug 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support